Navidea Biopharmaceuticals faces delisting from NYSE American, plans to move to OTC markets

This post was originally published on this site

https://i-invdn-com.investing.com/news/LYNXNPEC0L0PD_M.jpg

Despite the looming delisting, Navidea remains committed to its ‘Fix, Fund, Propel’ strategy. The company has a 15-day window to request a review of the decision and is currently awaiting the outcome of an application for delisting submitted to the Securities and Exchange Commission (SEC).

Even if delisted, Navidea will continue to be an SEC reporting company. Furthermore, the company is considering relisting on a national securities exchange in the future. Navidea reassured stakeholders that these developments would not impact its business operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.